Printer Friendly

MICROPROBE INITIATES COUNTERSUIT AGAINST GEN-PROBE

 BOTHELL, Wash., June 9 /PRNewswire/ -- MicroProbe Corporation, based in Bothell, Wash., today announced that it has answered the complaint from Gen-Probe for alleged patent infringement of Gen-Probe Inc.'s U.S. Patent No. 4,851,330 and has initiated a countersuit against Gen-Probe, a wholly-owned subsidiary of the Japanese company, Chugai Pharmaceutical Co., Ltd.
 Under the countersuit, MicroProbe holds that the so-called Kohne 330 patent is invalid and unenforcible, and that none of MicroProbe's activities and products infringe upon the patent, according to John Bishop, MicroProbe's chairman and chief executive officer.
 Because MicroProbe is based in Washington, the company has also requested that the litigation be transferred from the U.S. District Court for the Southern District of California in San Diego to the District Court for the Western District of Washington in Seattle.
 MicroProbe Corporation is developing practical applications of oligonucleotides for the diagnosis and treatment of infectious disease, utilizing proven principles of biochemical control. The company has a strong patent portfolio behind its technology, including 14 patents through its diagnostics and therapeutics divisions. In addition to producing nucleic acid probe-based systems for the rapid identification of infectious-disease microorganisms, MicroProbe is involved in research aimed at the discovery and development of new classes of therapeutics that selectively block genes and disease-causing proteins of chronic viral infections and certain cancers.
 -0- 6/9/93
 /CONTACT: Greg Sessler, chief financial officer of MicroProbe Corporation, 206-485-8566, or Charles Versaggi of Gable/Versaggi Biocommunications, 408-358-4162, for MicroProbe Corporation/


CO: MicroProbe Corporation ST: Washington State IN: MCT SU:

TM -- NY006 -- 6864 06/09/93 08:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1993
Words:263
Previous Article:DIANON SYSTEMS INC. ANNOUNCES TECHNOLOGY LICENSING AGREEMENT AND EQUITY INVESTMENT WITH APROGENEX, INC.
Next Article:VISA AND SPRINT INTRODUCE NEW GLOBAL CALLING SERVICE
Topics:


Related Articles
MICROPROBE RECEIVES PERMISSION TO MARKET ID SYSTEM FOR PERIODONTAL DISEASE-ASSOCIATED ORGANISMS IN 11 COUNTRIES
Vysis to defend patent licensed to Gen-Probe.
Gen-Probe Wins Appeal in Patent Infringement Case Against Enzo Biochem.
Survivors include his wife, 5 children and 2 stepchildren. Gen-Probe West Nile virus test now available to US blood centers; Chiron will distribute.
Gen-Probe granted summary judgment in Enzo patent lawsuit.
Clinical Trials of Procleix(R) Ultrio(TM) Assay Begin on Procleix TIGRIS(R) System.
Gen-Probe Granted Summary Judgment in Enzo Patent Lawsuit.
Appeals Court Affirms Summary Judgment in Favor of Gen-Probe in Enzo Patent Lawsuit.
Appeals court affirms summary judgment in favor of Gen-Probe in Enzo patent lawsuit.
Court dismisses Gen-Probe court action against Digene.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters